Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01650090
Recruitment Status : Active, not recruiting
First Posted : July 26, 2012
Last Update Posted : February 7, 2018
Information provided by (Responsible Party):
Eleison Pharmaceuticals LLC.

July 20, 2012
July 26, 2012
February 7, 2018
August 2012
December 2018   (Final data collection date for primary outcome measure)
Observed Relapse Free Interval (RFI) [ Time Frame: At relapse, estimated at 6-12 months average. ]
Observed relapse free interval (RFI) will be compared to historical controls. Relapse free interval is defined as the time of diagnosis of the previous relapse to time of diagnosis of the new relapse.
Same as current
Complete list of historical versions of study NCT01650090 on Archive Site
  • Median, 1, 2 and 5 year Overall Survival (OS) [ Time Frame: 1, 2 and 5 Years ]
    The percentage of patients alive at 1, 2 and 5 years and the median overall survival.
  • Median, 1, 2 and 5 year Event Free Survival (EFS) [ Time Frame: 1, 2 and 5 years ]
    The percentage of patients surviving without disease relapse at 1, 2 and 5 years and the median event free survival.
Same as current
Not Provided
Not Provided
Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma
Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma
To establish whether treatment with Inhaled Lipid Cisplatin (ILC) is effective in delaying/preventing pulmonary relapse in osteosarcoma patients in complete surgical remission following one or two prior pulmonary relapses.

ILC is a novel formulation of cisplatin, designed for inhalation by nebulization. The anticipated pulmonary benefits of ILC over systemic cisplatin therapy are threefold:

  • Increased local cisplatin concentrations
  • Sustained release of cisplatin in the lungs
  • Minimal systemic exposure to cisplatin

In this study, patients currently in surgical complete remission (CR) following one or two prior relapses of osteosarcoma involving pulmonary disease will be treated with ILC every two weeks for up to one year. ILC will be administered via nebulization.

Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Pulmonary Relapse of Osteosarcoma
Drug: Inhaled Lipid Cisplatin (ILC)
ILC is provided as cisplatin in a lipid complex suspended in a saline solution. Every two weeks, the patient will receive 36 mg/m2 (measured as concentration of cisplatin) of ILC via nebulization. Treatment may continue for up to 1 year.
Other Names:
  • Cisplatin
  • Lipid cisplatin complex
Experimental: ILC
Inhaled Lipid Cisplatin (ILC) will be administered every two weeks via nebulization and inhalation.
Intervention: Drug: Inhaled Lipid Cisplatin (ILC)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
Same as current
December 2018
December 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. History of osteosarcoma metastatic to the lung(s). (First or second pulmonary recurrence(s) removed by surgery, and previous second-line systemic chemotherapy is allowed).
  2. Patients must be macroscopically disease free following pulmonary metastectomy of a single or multiple lesions. Complete remission surgically (free of macroscopic disease) is required. Pleural disruption and/or microscopic positive margins are allowed.
  3. Age ≥13 years.
  4. Patients must have recovered sufficiently from all acute adverse effects of prior therapies, excluding alopecia.
  5. Patients must have an ECOG performance status of 0-2. (Lansky score of 50-100 if < 16 years old).
  6. Patients must have recovered sufficiently from surgery and have adequate airflow and pulmonary reserve. This decision should be at the investigator's discretion taking into consideration pre-surgery pulmonary function. (As a guideline: adequate airflow defined by a measured Forced Expiratory Volume (FEV1) not less than 50% of the predicted value and adequate pulmonary reserve as evidenced by a FEV1/FVC ratio of 65% or greater).
  7. Patients must have adequate renal function as defined by a serum creatinine of ≤ 1.5 mg/dl.
  8. Patients must have adequate liver function as defined by total bilirubin of ≤ 1.5 mg/dl and ALT or AST < 2.5 times the institution's upper normal limit.
  9. Patients must have adequate bone marrow function as defined by an absolute neutrophil count (ANC) of ≥ 1,000/mm3 and platelet count of ≥ 100,000/mm3.
  10. Signed informed consent including, where applicable, the consent of the patient's legal guardian.

Exclusion Criteria:

  1. Current extrapulmonary disease.
  2. Current macroscopic pulmonary lesions.
  3. Greater than 2 pulmonary recurrences.
  4. Greater than 4 weeks since thoracotomy rendering patient free of macroscopic disease.
  5. Females who are pregnant or breast-feeding.
  6. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study.
  7. Contraindication to or unwillingness to undergo multiple CT scans and chest X-rays.
  8. Unwillingness or inability to comply with the study protocol for any other reason.
  9. Participation in an investigational drug or device study or treatment with any anti-neoplastic agent within 14 days of the first day of dosing on this study
Sexes Eligible for Study: All
13 Years and older   (Child, Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Eleison Pharmaceuticals LLC.
Eleison Pharmaceuticals LLC.
Not Provided
Principal Investigator: Richard Gorlick, MD The Children's Hospital at Montefiore
Study Director: Forrest H Anthony, MD, PhD Eleison Pharmaceuticals
Eleison Pharmaceuticals LLC.
February 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP